To reach the next value inflection
LicenseRx asset brief
LZK and DLK Inhibitors to Target LZK and Suppress MYC Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and Tumor Regression
Probability of Success
25% · grade B · Medium data confidence
Model PoS 25% (grade B, medium data confidence). Strongest signals: Data maturity, Modality feasibility. Biggest drag: IP position.
Data maturity (22%)
63
Preclinical; in vivo data, clinical reference.
IP position (16%)
45
No clear patent status in public data -- treat IP as unpriced until counsel confirms.
Modality feasibility (14%)
82
Small molecule -- well-trodden regulatory and CMC path.
Indication pull (14%)
82
Oncology -- active buyer appetite.
Competitive whitespace (12%)
66
Crowded oncology field; multi-modal differentiation.
Translational evidence (12%)
70
Public evidence mentions: clinical, in vivo, mouse.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →